Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study

Current Therapeutic Research - Clinical and Experimental

Volumn 67, Issue 1, 2006, Pages 55-65

  Khatri, Bhupendra O ^a   Wroblewski, Mary ^a   Kramer, John ^a   Dukic, Mary ^a   Poplar, Arleen ^a   Anderson, A J ^a  

^a Center for Neurological Disorders   (United States)

Author keywords

mitoxantrone; multiple sclerosis; nonresponders; responders

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; METHYLPREDNISOLONE; MITOXANTRONE; ONDANSETRON; PROCHLORPERAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; ASSISTED VENTILATION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISABILITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FUNCTION; HOSPITALIZATION; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MENSTRUAL IRREGULARITY; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC EXAMINATION; OPEN STUDY; PHYSICAL EXAMINATION; PREMEDICATION; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SEPSIS; SEPTICEMIA; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UROGENITAL TRACT INFECTION; VOMITING;

EID: 33744925908     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2006.02.004     Document Type: Article

References (18)

1. [package insert]. Novatrone (mitoxantrone for injection concentrate) (2000), Immunex Corporation, Seattle, Wa
2. Hartung H.P., Gonsette R., Konig N., et al., Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
3. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
4. Hauser S.L., Dawson D.M., Lehrichet J.R., et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308 (1983) 173-180
5. Edan G., Miller D., Clanet M., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62 (1997) 112-118
6. Millefiorini E., Gasperini C., Pozzilli C., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome. J Neurol 244 (1997) 153-159
7. Goodin D.S., Arnason B.G., Coyle P.K., et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 1332-1338
8. Noseworthy J.H., Hopkins M.B., Vandervoort M.K., et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43 (1993) 1401-1406
9. van de Wyngaert F.A., Beguin C., D'Hooghe M.B., et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multi-ple sclerosis. Acta Neurol Belg 101 (2001) 210-216
10. Avasarala J.R., Cross A.H., Clifford D.B., et al. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 9 (2003) 59-62
11. Gbadamosi J., Munchau A., Weiller C., and Schafer H. Severe heart failure in a young multiple sclerosis patient. J Neurol 250 (2003) 241-242
12. Mogenet I., Simiand-Erdociain E., Canonge J.M., and Pris J. Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis. Ann Pharmacother 37 (2003) 747-748
13. Vicari A.M., Ciceri F., Folli F., et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 12 (1998) 441-442
14. Cattaneo C., Almici C., Borlenghi E., et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 17 (2003) 985-986
15. Brassat D., Recher C., Waubant E., et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 59 (2002) 954-955
16. Ghalie R.G., Mauch E., Edan G., et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8 (2002) 441-445
17. Heesen C., Bruegmann M., Gbdamosi J., et al. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 9 (2003) 213-214
18. Weinshenker B.G. The natural history of multiple sclerosis. Neurol Clin 13 (1995) 119-146